Reversal of antiparkinsonian drug toxicity by physostigmine: a controlled study.
D000293:Adolescent; D000328:Adult; D000647:Amnesia / Q000139:chemically induced; D000928:Antidepressive Agents / Q000009:adverse effects; D000978:Antiparkinson Agents / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects; D001007:Anxiety; D001590:Benztropine / Q000009:adverse effects; D005260:Female; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D007273:Injections, Intramuscular; D010640:Phenothiazines; D010830:Physostigmine / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D011605:Psychoses, Substance-Induced / Q000188:drug therapy* / Q000209:etiology; D012559:Schizophrenia / Q000188:drug therapy; D014326:Tropanes
D000928:Antidepressive Agents; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D010640:Phenothiazines; D010919:Placebos; D014326:Tropanes; D001590:Benztropine; D010830:Physostigmine